Impact of short-form, case-based continuing medical education on clinician knowledge and competence in optimizing CAR T-cell therapy for Relapsed/Refractory multiple myeloma

Abstract Background: Emerging evidence underscores the pivotal role of immunotherapies targeting B-cell maturation antigen (BCMA) in improving outcomes for multiple myeloma (MM) patients. With recent FDA approvals of CAR T-cell therapies for relapsed/refractory MM (RRMM) following multiple prior treatments, oncology clinicians urgently require up-to-date guidance to navigate evolving treatment options, combination strategies, and earlier-line interventions. Purpose: This study evaluated whether digital, short-form, case-based education enhances clinicians' knowledge and competence in optimizing CAR T-cell therapy for RRMM. Methods: US-based hematologists, hematologist-oncologists, nurse practitioners (NPs), and physician assistants (PAs) participated in an accredited live satellite symposium at ASH 2024 titled “A Step-by-Step Approach to CAR T-Cell Therapy for RRMM: From Bridging to Sequencing and Adverse Event Management.” Following the live event, the symposium was adapted as a 15-minute on-demand e-learning program. Pre- and post-activity assessments measured learners' baseline knowledge and competence and the impact of the intervention. Data were analyzed in aggregate and by specialty. Results: As of August 4, 2025, 4,591 clinicians completed the activity. Knowledge and competence improved significantly among hematologist-oncologists (26%), NPs (35%), and PAs (33%). Notable gains were seen in understanding the latest CAR T-cell regimens (12% increase), patient eligibility criteria (28% increase), and adverse event management (39% increase). Post-activity, learners reported increased confidence using CAR T-cell therapies, and 62% expressed interest in further education on emerging data for earlier-line treatments. Conclusions: Digital, short-form, case-based CME effectively enhanced clinician knowledge and competence in CAR T-cell therapy for RRMM and identified ongoing educational gaps to inform future efforts.

Authors

Institutions

Publication Details

Journal
Blood
Published
2025-11-03
DOI
https://doi.org/10.1182/blood-2025-8220
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Impact of short-form, case-based continuing medical education on clinician knowledge and competence in optimizing CAR T-cell therapy for Relapsed/Refractory multiple myeloma

Jesús G. Berdeja, Adriana Rossi, Meghan Coulehan, Emily Kitterman et al.
Blood
CAR-T cell therapy research
article

Impact of short-form, case-based continuing medical education on clinician knowledge and competence in optimizing CAR T-cell therapy for Relapsed/Refractory multiple myeloma

Jesús G. Berdeja, Adriana Rossi, Meghan Coulehan, Emily Kitterman, Aisha Suhail
article en

Abstract

Abstract Background: Emerging evidence underscores the pivotal role of immunotherapies targeting B-cell maturation antigen (BCMA) in improving outcomes for multiple myeloma (MM) patients. With recent FDA approvals of CAR T-cell therapies for relapsed/refractory MM (RRMM) following multiple prior treatments, oncology clinicians urgently require up-to-date guidance to navigate evolving treatment options, combination strategies, and earlier-line interventions. Purpose: This study evaluated whether digital, short-form, case-based education enhances clinicians' knowledge and competence in optimizing CAR T-cell therapy for RRMM. Methods: US-based hematologists, hematologist-oncologists, nurse practitioners (NPs), and physician assistants (PAs) participated in an accredited live satellite symposium at ASH 2024 titled “A Step-by-Step Approach to CAR T-Cell Therapy for RRMM: From Bridging to Sequencing and Adverse Event Management.” Following the live event, the symposium was adapted as a 15-minute on-demand e-learning program. Pre- and post-activity assessments measured learners' baseline knowledge and competence and the impact of the intervention. Data were analyzed in aggregate and by specialty. Results: As of August 4, 2025, 4,591 clinicians completed the activity. Knowledge and competence improved significantly among hematologist-oncologists (26%), NPs (35%), and PAs (33%). Notable gains were seen in understanding the latest CAR T-cell regimens (12% increase), patient eligibility criteria (28% increase), and adverse event management (39% increase). Post-activity, learners reported increased confidence using CAR T-cell therapies, and 62% expressed interest in further education on emerging data for earlier-line treatments. Conclusions: Digital, short-form, case-based CME effectively enhanced clinician knowledge and competence in CAR T-cell therapy for RRMM and identified ongoing educational gaps to inform future efforts.

BloodVol. 146(Supplement 1)
Mount Sinai Hospital (US), Mount Sinai Hospital (US), Swanson Center (US), Centerstone (US)
Openalex Percentile: Top 46%
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.